Abstract
This study addresses the question of how hospitals respond to the cross price incentives inherent in reimbursements based on diagnosis‐related groups (DRG). Unique market‐wide administrative data allow to exploit a natural experiment in Germany in which the relative attractiveness of greatly divergent reimbursements for clinically similar patients changes in the market for sepsis conditions on January 1, 2010. This natural experiment provides—unintentionally—extra reimbursements in cases in which hospitals reorganize transfers for deceasing patients to other facilities, alter the time of death, the choice of the condition being chiefly responsible for the hospital admiss...
Read the full post at
Wiley: Health Economics: Table of Contents